Thomas Welte

Current Position

Principal Investigator, Fellow in Nephrology

Academic Education

2006 - 2013

Medical School (University of Freiburg)

Advanced Qualifications

2022	Board Certification Internal Medicine
2021	Board Certification Emergency Medicine
2014	Doctoral degree in Medicine (Dr. med.), University of Freiburg

Postgraduate Positions

2022 - present	Fellow in Nephrology, Principal Investigator, Renal Division, Medical Center - University of Freiburg
2021 - 2022	Postdoctoral Research Fellow, Medical Center - University of Freiburg
2019 - present	Visiting Scientist, Friedrich Miescher Institute for Biomedical Research - Basel, Switzerland
2019 - 2022	Residency in Internal Medicine, Medical Center - University of Freiburg
2017 - 2019	Postdoctoral Research Fellow, Friedrich Miescher Institute for Biomedical Research – Basel, Switzerland
2014 – 2017	Residency in Internal Medicine, Medical Center - University of Freiburg

Link to all publications of Thomas Welte: PubMed

Publications on CRC 1453 funding

Arnold F, Kappes J, Rottmann FA, Westermann L, Welte T. HbA1c-dependent projection of long-term renal outcomes. J Intern Med (2023). Westermann L, Rottmann FA, Hug MJ, Staudacher DL, Wobster R, Arnold F, Welte T. Clinical covariates influencing clinical outcomes in primary membranous nephropathy. BMC Nephrol (2023). Welte T, Westermann L, Kappes J, Schramm MA, Bemtgen X, Staudacher DL, Hug MJ, Venhoff N, Arnold F. Identification of covariates modulating B-cell repopulation kinetics in subjects receiving rituximab treatment. Arthritis Rheumatol (2023). Jaki L, Weigang S, Kern L, Kramme S, Wrobel AG, …, Neumann-Haefelin E, Schnepf D, Welte T, Kochs G, Huzly D, Panning M, Fuchs J. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient. Nat Commun (2023). Ganner A, Philipp A, Lagies S, Wingendorf L, Wang L, Pilz F, Welte T, …, Frew IJ, Walz G, Neumann-Haefelin E. SCD5 Regulation by VHL Affects Cell Proliferation and Lipid Homeostasis in ccRCC. Cells (2023). Welte T, Arnold F, Westermann L, Rottmann FA, Hug MJ, Neumann-Haefelin E, Ganner A. Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study. BMC Nephrol (2023). Rottmann FA, Breiden AK, Bemtgen X, Welte T, Supady A, Wengenmayer T, Staudacher DL. Levosimendan in acute heart failure with severely reduced kidney function, a propensity score matched registry study. Front Cardiovasc Med (2022). Arnold F, Huzly D, Tanriver Y, Welte T. Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease. BMC Infect Dis (2022).